USPTO serial 88598278
CELLREGEN
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- NEVILLE, BRIAN
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with CELLREGEN?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
John C. Stringham
John C. Stringham WORKMAN NYDEGGER60 E. SOUTH TEMPLE, SUITE 1000SALT LAKE CITY, UT 84111UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Biological preparations for others, namely, human cells and tissue for scientific and research use; Cells and biological tissue, namely, human tissue, stem cells, bone marrow, amniotic fluid and blood, for scientific research and use in cellular therapies; biological preparations for others, namely, human cells and tissue, for use in the research of treatment of degenerative diseases, wound healing, and cell therapy | ACTIVE | — |
| 005 | Biological and chemical products for use by clinicians in regenerative medicine for medical purposes, namely, cellular healing therapies and regenerative medicine | ACTIVE | — |
| 035 | Business consulting and industry collaboration in the field of clinical trials, namely, clinical data and regulatory submission management on behalf of medical, biopharmaceutical and biotechnology companies to assist them with clinical research, clinical trials, applications for drug approval and product development; providing product commercialization assistance in the field of cellular therapy and regenerative medicine; commercialization services in the field of cellular therapy and regenerative medicine | ACTIVE | — |
| 040 | Contract manufacturing, namely, manufacture of cellular therapies and regenerative medicines; conducting manufacturing support, namely, development of operating procedures and batch records, cell expansion, master and working cell bank production and clinical trials in the field of cellular therapy and regenerative medicine | ACTIVE | — |
| 041 | Academic support, namely, providing clinical programs, academic conferences, training, mentoring and fellowships in the field of clinical trials, technology transfer, product development, optimization, manufacturing and commercialization; educational services in the field of cellular therapy and regenerative medicine | ACTIVE | — |
| 042 | Conducting clinical trials and research for others in the field of cellular therapy and regenerative medicine; providing medical and scientific research information in the field of clinical trials for cellular therapy and regenerative medicine; Product research and development; Product development consultation; Product research and development services for others in the field of cellular therapy and regenerative medicine; scientific development in the field of stem cells and regenerative medicine; scientific research, discovery, technology transfer, process development and clinical trials in the field of cellular therapy and regenerative medicine | ACTIVE | — |
| 044 | Medical services in the field of cell-based therapies, including the use of biological cells and tissue in the delivery of cell-based therapies and regenerative medicine; Cell therapy services for the treatment of degenerative diseases, wounds, hematologic diseases, hematologic disorders and immuno-therapy; providing consultancy and information relating to these cell therapies for medical purposes; administration of cell therapies for the treatment of disorders, diseases, and injuries; medical services, namely, isolation of regenerative cells relating to cell therapy services, stem cell collection, processing, phenotypic characterization, infusion and storage for medical and scientific purposes; providing medical therapies, namely, stem cell therapies and therapies for regeneration of human tissues and cells; providing educational medical information about cellular therapy and regenerative medicines | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by University of Utah Research Foundation
- Other trademarks owned by University of Utah Research Foundation
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 035
- Other trademarks in Class 040
- Other trademarks in Class 041
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named CELLREGEN
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 25, 2021 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Oct 25, 2021 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Mar 23, 2021 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jan 26, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 26, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 6, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 17, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 16, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 15, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 15, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 24, 2020 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 24, 2020 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 24, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 4, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 4, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 4, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 4, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 4, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 4, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 2, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 11, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 2, 2019 | NWAP | NEW APPLICATION ENTERED | — |